HDAC6 and Miyoshi myopathy: Indeed, the first selective HDAC6 inhibitor ACY-1215 (ricolinostat) has been examined as a single agent or in combination with bortezomib and dexamethasone for relapsed or refractory MM in a phase I/II study126.